Leandro Jonata de Carvalho Oliveira
YOU?
Author Swipe
View article: OP13 Prioritizing Real-World Data In Next-Generation Health Technology Assessment: Insights From Oncotype DX Breast Recurrence Score® And Chemotherapy Recommendations For Breast Cancer In Brazil
OP13 Prioritizing Real-World Data In Next-Generation Health Technology Assessment: Insights From Oncotype DX Breast Recurrence Score® And Chemotherapy Recommendations For Breast Cancer In Brazil Open
Introduction Mounting evidence shows that gene expression signatures in early breast cancer enable more precise chemotherapy recommendations, targeting those most likely to benefit and safely avoiding it for others. International guideline…
View article: Budget Impact of the Oncotype DX Test in Early-Stage Breast Cancer for the Brazilian Private Health Care System
Budget Impact of the Oncotype DX Test in Early-Stage Breast Cancer for the Brazilian Private Health Care System Open
PURPOSE Adjuvant chemotherapy decisions for early-stage hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–) breast cancer remain challenging, requiring a balance between treatment efficacy and avoidin…
View article: Cancer outcomes in patients eligible for adjuvant cyclin-dependent kinase 4 and 6 inhibitors but spared adjuvant chemotherapy by Oncotype Dx: A multicenter retrospective GBECAM 0520 study
Cancer outcomes in patients eligible for adjuvant cyclin-dependent kinase 4 and 6 inhibitors but spared adjuvant chemotherapy by Oncotype Dx: A multicenter retrospective GBECAM 0520 study Open
HR+/HER2- eBC patients eligible for CDK4/6i but spared CT by ODX are a minority and have excellent outcomes with ET alone. This highlights the potential benefits of integrating genomic and clinical risk stratification to refine therapeutic…
View article: Understanding and overcoming CDK4/6 inhibitor resistance in HR+/HER2− metastatic breast cancer: clinical and molecular perspectives
Understanding and overcoming CDK4/6 inhibitor resistance in HR+/HER2− metastatic breast cancer: clinical and molecular perspectives Open
This narrative review explores the mechanisms underlying resistance to cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in hormone receptor (HR)-positive metastatic breast cancer (MBC), a critical challenge in contemporary oncology. Despit…
View article: A portrait of germline pathogenic variants in high and moderate penetrance breast cancer genes in Brazil
A portrait of germline pathogenic variants in high and moderate penetrance breast cancer genes in Brazil Open
Introduction The prevalence of germline pathogenic/likely pathogenic variants (P/LP) in high and moderate penetrance (HMP) genes is approximately 7%–10% among breast cancer (BC) patients. The prevalence and spectrum of BC P/LP variants are…
View article: Real-World Treatment Patterns and Outcomes in Hormone Receptor Positive HER2 Negative Early-Stage Breast Cancer in a Private Community Oncology Practice of Brazil
Real-World Treatment Patterns and Outcomes in Hormone Receptor Positive HER2 Negative Early-Stage Breast Cancer in a Private Community Oncology Practice of Brazil Open
Purpose This study aims to assess the disease characteristics, practice patterns and real-world outcomes of patients (pts) with HR positive (+)/HER2 negative (-) early breast cancer (EBC) treated in Brazil's largest network of community on…
View article: The somatic mutation profile of estrogen receptor-positive HER2-negative metastatic breast cancer in Brazilian patients
The somatic mutation profile of estrogen receptor-positive HER2-negative metastatic breast cancer in Brazilian patients Open
Background Breast cancer is the leading cause of cancer death among women worldwide. Studies about the genomic landscape of metastatic breast cancer (MBC) have predominantly originated from developed nations. There are still limited data o…
View article: Real-world treatment outcomes in HR+ HER2- metastatic breast cancer patients treated with CDK4/6 inhibitors: Results from a reference center in Brazil
Real-world treatment outcomes in HR+ HER2- metastatic breast cancer patients treated with CDK4/6 inhibitors: Results from a reference center in Brazil Open
Our results confirm the efficacy and tolerability of CDK4/6i in routine clinical practice. This is the first real-world data describing and comparing the efficacy and toxicity of CDK4/6i in the Brazilian population.
View article: Subgroup analysis of Brazilian participants of a medical leadership competencies instrument: a cross-sectional survey study of the Latin American Cooperative Oncology Group (LACOG) and the Academy of Leadership Sciences Switzerland (ALSS)
Subgroup analysis of Brazilian participants of a medical leadership competencies instrument: a cross-sectional survey study of the Latin American Cooperative Oncology Group (LACOG) and the Academy of Leadership Sciences Switzerland (ALSS) Open
Introduction: We previously published the results of a medical leadership (ML) competencies instrument applied to Latin-American (LA) physicians with a leadership position, which disclosed meaningful differences in the valuation of specifi…
View article: Impact of the COVID-19 Pandemic on Cancer Staging: An Analysis of Patients With Breast Cancer From a Community Practice in Brazil
Impact of the COVID-19 Pandemic on Cancer Staging: An Analysis of Patients With Breast Cancer From a Community Practice in Brazil Open
PURPOSE A nationwide lockdown was enforced in Brazil starting in March 2020 because of the COVID-19 pandemic when cancer screening activities were reduced. In this study, we evaluated the impact of the COVID-19 pandemic on breast cancer (B…
View article: Current Molecular Profile of Gastrointestinal Stromal Tumors and Systemic Therapeutic Implications
Current Molecular Profile of Gastrointestinal Stromal Tumors and Systemic Therapeutic Implications Open
Gastrointestinal stromal tumors (GISTs) are malignant mesenchymal tumors arising from the intestinal pacemaker cells of Cajal. They compose a heterogenous group of tumors due to a variety of molecular alterations. The most common gain-of-f…
View article: Vitamin D and colorectal cancer – A practical review of the literature
Vitamin D and colorectal cancer – A practical review of the literature Open
Colorectal cancer (CRC) is the third leading cause of cancer-related mortality in the United States and the second cause worldwide. Its incidence rates have been decreasing in the overall population in the US in the past few decades, but w…
View article: Cost-effectiveness analysis of Oncotype DX from a Brazilian private medicine perspective: a GBECAM multicenter retrospective study
Cost-effectiveness analysis of Oncotype DX from a Brazilian private medicine perspective: a GBECAM multicenter retrospective study Open
Background: Oncotype DX (ODX) is a validated assay for the prediction of risk of recurrence and benefit of chemotherapy (CT) in both node negative (N0) and 1–3 positive nodes (N1), hormone receptor positive (HR+), human epidermal growth fa…
View article: Alectinib activity in chemotherapy-refractory metastatic RET-rearranged non-small cell lung carcinomas: A case series
Alectinib activity in chemotherapy-refractory metastatic RET-rearranged non-small cell lung carcinomas: A case series Open
Although this is a small single center evaluation, alectinib was well tolerated and demonstrated clinical activity against advanced RET-rearranged NSCLCs, suggesting its potential role in this specific subset of malignancies. Clinical tria…
View article: Successful osimertinib rechallenge following drug-induced pneumonitis after previous anti-PDL1 exposure
Successful osimertinib rechallenge following drug-induced pneumonitis after previous anti-PDL1 exposure Open
Osimertinib is a first-line treatment option for patients with metastatic non-small cell lung cancer (NSCLC) harbouring EGFR mutations. Pneumonitis is a severe adverse event (AE) related to osimertinib treatment which appears to be more fr…
View article: The first report of molecular characterized BRD4-NUT carcinoma in Brazil: a case report
The first report of molecular characterized BRD4-NUT carcinoma in Brazil: a case report Open
NUT midline carcinoma is usually very aggressive. Currently, there is no standard of care for treatment of NUT midline carcinoma. The definitive diagnosis must be by demonstration of NUTM1 rearrangement. Immunohistochemical staining of gre…
View article: Bevacizumab-associated osteonecrosis of the femur and tibia
Bevacizumab-associated osteonecrosis of the femur and tibia Open
Osteonecrosis is a multifactorial process that can affect different skeletal structures of the body. Osteonecrosis of the jaw associated with bevacizumab, steroids and bisphosphonates, alone or in combination, is a well-documented phenomen…
View article: COMPARATIVE EFFECTIVENESS OF BREAST CONSERVING SURGERY VERSUS MASTECTOMY ON SURVIVAL IN BREAST CANCER PATIENTS THAT RECEIVED NEOADJUVANT CHEMOTHERAPY AND POST-OPERATIVE RADIATION THERAPY
COMPARATIVE EFFECTIVENESS OF BREAST CONSERVING SURGERY VERSUS MASTECTOMY ON SURVIVAL IN BREAST CANCER PATIENTS THAT RECEIVED NEOADJUVANT CHEMOTHERAPY AND POST-OPERATIVE RADIATION THERAPY Open
Objectives:The aim of this study was to determine whether there were differences in survival outcomes of matched breast cancer patients undergoing breast-conserving surgery (BCS) versus mastectomy that received neoadjuvant chemotherapy (NA…
View article: ANALYSIS OF CLINICAL OUTCOMES BASED ON MOLECULAR SUBTYPES IN PATIENTS WITH BREAST CANCER THAT RECEIVED NEOADJUVANT CHEMOTHERAPY
ANALYSIS OF CLINICAL OUTCOMES BASED ON MOLECULAR SUBTYPES IN PATIENTS WITH BREAST CANCER THAT RECEIVED NEOADJUVANT CHEMOTHERAPY Open
Objectives: To evaluate the survival outcomes based on molecular subtypes of patients with breast cancer that received neoadjuvant chemotherapy (NAC).Methodology: We performed a retrospective analysis of all non-metastatic breast cancer pa…
View article: Atypical response with bone pseudoprogression in a patient receiving nivolumab for advanced cutaneous squamous cell carcinoma
Atypical response with bone pseudoprogression in a patient receiving nivolumab for advanced cutaneous squamous cell carcinoma Open
Currently, there is no established standard of care for patients with metastatic CSCC. Based on the mechanisms of CSCC carcinogenesis has been postulated that these tumors may be amenable to PD-1/PD-L1 blockade.This case illustrates a pati…